Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037067 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL12933846 | 0.95 | EDNRA (0.90) | EDNRAEDNRB | |
| SCHEMBL12933849 | 0.95 | EDNRA (0.90) | EDNRAEDNRB | |
| SCHEMBL12933883 | 0.94 | EDNRA (0.88) | EDNRAEDNRB | |
| SCHEMBL12933850 | 0.92 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL12933851 | 0.92 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL12933869 | 0.92 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL12933855 | 0.92 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL434551 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL12933877 | 0.91 | EDNRA (0.82) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| EP-2170278-A2 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3-{Ý(3,4 DIMETHYL-5-ISOXAZOLYL)AMINO]SULFONYL}-2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009002490-A2 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3-{[(3,4 DIMETHYL-5-ISOXAZOLYL)AMINO]SULFONYL}-2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | claimed |
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS INC. | 2008-12-25 | — | — | US | claimed |
| EP-1533311-B1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC (US) | 2007-04-25 | — | — | EP | claimed |
| EP-1244657-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-10-02 | — | — | EP | claimed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | claimed |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-27 | — | — | US | claimed |
| WO-2001049685-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| EP-4747258-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4736949-A2 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | REMD BIOTHERAPEUTICS INC (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4687883-A2 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-1244657-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-27 | — | — | US | disclosed |
| WO-2001049685-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | AADAC, B3GNT2, AANAT | EDNRA 1571/4885EDNRB 1119/4885 |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | EDNRA, EDNRB, FCGR2A | EDNRA 1/4885EDNRB 2/4885 |
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | TRPM5, TRPM6, TRPM2 | EDNRA 4168/4885EDNRB 3493/4885 |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.